Загрузка...
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
BACKGROUND: Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) can result in impressive response rates and durable disease remission...
Сохранить в:
| Опубликовано в: : | Ann Oncol |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6336005/ https://ncbi.nlm.nih.gov/pubmed/30395155 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy495 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|